175 related articles for article (PubMed ID: 16246568)
1. Treatment of older patients with AML.
Büchner T; Berdel WE; Wörmann B; Schoch C; Haferlach T; Schnittger S; Kern W; Aul C; Lengfelder E; Schumacher A; Reichle A; Staib P; Balleisen L; Eimermacher H; Grüneisen A; Rasche H; Sauerland MC; Heinecke A; Mesters RM; Serve HL; Kienast J; Hiddemann W
Crit Rev Oncol Hematol; 2005 Nov; 56(2):247-59. PubMed ID: 16246568
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukaemia (AML): treatment of the older patient.
Büchner T; Hiddemann W; Schoch C; Haferlach T; Sauerland MC; Heinecke A
Best Pract Res Clin Haematol; 2001 Mar; 14(1):139-51. PubMed ID: 11355928
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
4. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
5. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
6. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
7. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T; Berdel WE; Haferlach C; Haferlach T; Schnittger S; Müller-Tidow C; Braess J; Spiekermann K; Kienast J; Staib P; Grüneisen A; Kern W; Reichle A; Maschmeyer G; Aul C; Lengfelder E; Sauerland MC; Heinecke A; Wörmann B; Hiddemann W
J Clin Oncol; 2009 Jan; 27(1):61-9. PubMed ID: 19047294
[TBL] [Abstract][Full Text] [Related]
8. Remission induction therapy: the more intensive the better?
Büchner T; Hiddemann W; Berdel W; Wörmann B; Löffler H; Schoch C; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Andreesen R; Balleisen L; Haase D; Eimermacher H; Aul C; Rasche H; Uhlig J; Grüneisen A; Reis HE; Hartlapp J; Hirschmann WD; Weh HJ; Pielken HJ; Gassmann W; Sauerland MC; Heinecke A
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S41-4. PubMed ID: 11587366
[TBL] [Abstract][Full Text] [Related]
9. [Allogeneic stem cell transplantation in the management of acute myeloid leukemia].
Schmid C; Kolb HJ
Med Klin (Munich); 2007 Apr; 102(4):317-23. PubMed ID: 17426935
[TBL] [Abstract][Full Text] [Related]
10. [Elderly patients with acute myeloid leukemia: characteristics in biology, patients, and treatment].
Wedding U; Bokemeyer C; Meran JG; ; ;
Med Klin (Munich); 2003 Apr; 98(4):193-207. PubMed ID: 12715143
[TBL] [Abstract][Full Text] [Related]
11. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia: treatment over 60.
Büchner T; Hiddemann W; Berdel W; Wörmann B; Schoch C; Löffler H; Haferlach T; Schumacher A; Staib P; Balleisen L; Grüneisen A; Rasche H; Aul C; Heyll A; Lengfelder E; Ludwig WD; Maschmeyer G; Eimermacher H; Karow J; Frickhofen N; Hirschmann WD; Sauerland MC;
Rev Clin Exp Hematol; 2002 Mar; 6(1):46-59; discussion 86-7. PubMed ID: 12060483
[TBL] [Abstract][Full Text] [Related]
13. Progress in acute myelogenous leukemia.
Gale RP
Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
Doubek M; Palasek I; Brychtova Y; Buchtova I; Mayer J
Neoplasma; 2005; 52(5):411-4. PubMed ID: 16151586
[TBL] [Abstract][Full Text] [Related]
15. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
16. New agents in post-remission therapy.
Stone RM
Best Pract Res Clin Haematol; 2010 Dec; 23(4):475-9. PubMed ID: 21130410
[TBL] [Abstract][Full Text] [Related]
17. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
18. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
Tallman MS; Pérez WS; Lazarus HM; Gale RP; Maziarz RT; Rowe JM; Marks DI; Cahn JY; Bashey A; Bishop MR; Christiansen N; Frankel SR; García JJ; Ilhan O; Laughlin MJ; Liesveld J; Linker C; Litzow MR; Luger S; McCarthy PL; Milone GA; Pavlovsky S; Phillips GL; Russell JA; Saez RA; Schiller G; Sierra J; Weiner RS; Zander AR; Zhang MJ; Keating A; Weisdorf DJ; Horowitz MM
Biol Blood Marrow Transplant; 2006 Feb; 12(2):204-16. PubMed ID: 16443518
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
